Taste acuity improvement - objective outcome (continuous) - individual taste sensations · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
Zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… showed no clear difference in taste acuity improvement - objective outcome (continuous) -… compared with placebo; GRADE not reported.
1 finding from 1 review
Interventions for managing taste disturbances 2017 · Cochrane All outcomesChronic renal failure
Results (Mahajan 1980, chronic renal failure; Analysis 1.3): mean difference by taste sensation - salt MD 285 (95% CI 238.75 to 331.25); sweet MD 190 (142.36 to 237.64); sour MD 10 (-16.43 to 36.43); bitter MD 2.40…
1 study · 22 participants
GRADE not reported
Taste acuity improvement - objective outcome (continuous) - taste detection (cross-over trial) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (continuous) - taste… compared with placebo (very low certainty).
1 finding from 1 review
Taste acuity improvement - objective outcome (continuous) - taste recognition (cross-over trial) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (continuous) - taste… compared with placebo (very low certainty).
1 finding from 1 review
Taste acuity improvement - objective outcome (continuous data) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (continuous data) compared with placebo (very low certainty).
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether pilocarpine changes xerostomia (continuous, combined SMD) compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Daily mean opiate intake per hour · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) led to lower daily mean opiate intake per hour compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review
Average pain scores (0-100 VAS) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) showed no clear difference in average pain scores (0-100 VAS) compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review
Duration of pain control therapy (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Morphine via patient-controlled analgesia (PCA) led to lower duration of pain control therapy (days) compared with morphine via continuous infusion (CI); GRADE not reported.
1 finding from 1 review